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ABSTRACT
Objective: To investigate serum neurofilament light chain (NfL) concentrations in frontotemporal
dementia (FTD) and to see whether they are associated with the severity of disease.
Methods: Serum sampleswere collected from74participants (34with behavioral variant FTD [bvFTD],
3 with FTD and motor neuron disease and 37 with primary progressive aphasia [PPA]) and 28 healthy
controls. Twenty-four of the FTD participants carried a pathogenic mutation in C9orf72 (9),
microtubule-associated protein tau (MAPT; 11), or progranulin (GRN; 4). Serum NfL concentrations
were determined with the NF-Light kit transferred onto the single-molecule array platform and com-
pared between FTD and healthy controls and between the FTD clinical and genetic subtypes. We also
assessed the relationship between NfL concentrations and measures of cognition and brain volume.
Results: Serum NfL concentrations were higher in patients with FTD overall (mean 77.9 pg/mL [SD
51.3 pg/mL]) than controls (19.6 pg/mL [SD 8.2 pg/mL]; p , 0.001). Concentrations were also
significantly higher in bvFTD (57.8 pg/mL [SD 33.1 pg/mL]) and both the semantic and nonfluent
variants of PPA (95.9 and 82.5 pg/mL [SD 33.0 and 33.8 pg/mL], respectively) compared with
controls and in semantic variant PPA compared with logopenic variant PPA. Concentrations were
significantly higher than controls in both the C9orf72 andMAPT subgroups (79.2 and 40.5 pg/mL
[SD 48.2 and 20.9 pg/mL], respectively) with a trend to a higher level in the GRN subgroup
(138.5 pg/mL [SD 103.3 pg/mL). However, there was variability within all groups. Serum concen-
trations correlated particularly with frontal lobe atrophy rate (r 5 0.53, p 5 0.003).
Conclusions: Increased serum NfL concentrations are seen in FTD but show wide variability within
each clinical and genetic group. Higher concentrationsmay reflect the intensity of the disease in FTD
and are associated with more rapid atrophy of the frontal lobes. Neurology® 2016;87:1329–1336
GLOSSARY
bvFTD 5 behavioral variant frontotemporal dementia; FTD 5 frontotemporal dementia; GENFI 5 Genetic Frontotemporal
Dementia Initiative; lvPPA5 logopenic variant of primary progressive aphasia;MND5motor neuron disease;NfL5 neurofilament
light chain; nfvPPA 5 nonfluent variant of primary progressive aphasia; PPA 5 primary progressive aphasia; PPA-NOS 5 primary
progressive aphasia not otherwise specified; Simoa 5 single-molecule array; svPPA 5 semantic variant of primary progressive
aphasia.
Frontotemporal dementia (FTD) is a common cause of early-onset dementia.1 Clinically, patients
present with either changes in personality (behavioral variant FTD [bvFTD]) or impaired language
(primary progressive aphasia [PPA]), although overlap with motor neuron disease (FTD-MND) is
not uncommon.1 FTD has an autosomal dominant genetic cause in around a quarter of people,
with mutations in the progranulin (GRN), chromosome 9 open reading frame 72 (C9orf72), and
microtubule-associated protein tau (MAPT) genes being commonest.2
Few fluid biomarkers have been investigated in FTD, although there have now been a number
of studies of neurofilament concentration in the CSF.3–11 Higher neurofilament light chain
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(NfL) levels are believed to represent axonal
degeneration,12,13 and while early studies
showed variability in CSF concentrations in
FTD,4–10 a more recent study has suggested
that CSF NfL levels correlate with disease
severity.11
There is considerable interest in developing
blood-based biomarkers because of their con-
venience and higher acceptability relative to
CSF. NfL can be measured in serum with stan-
dard immunoassay formats,14 but those based on
ELISA or electrochemiluminescence methods
lack the analytical sensitivity to measure low lev-
els. For this reason, we developed an immuno-
assay based on the single-molecule array (Simoa)
technique15 that allows quantification down to
subfemtomolar concentrations (,1 pg/mL) of
the analyte and is 25-fold more sensitive than
the previous electrochemiluminescence-based
method.16 Using this assay, we aimed to investi-
gate serum NfL concentrations in FTD. Our
hypotheses were that serum NfL concentration
would be elevated in patients with FTD com-
pared with healthy controls, that concentrations
would vary between FTD subgroups, and that
increased serum NfL levels would reflect the dis-
ease intensity or rate of progression.
METHODS Seventy-four participants were consecutively re-
cruited from the University College London FTD study: 34 partici-
pants with bvFTD according to Rascovsky criteria,17 3 participants
with FTD-MND,18 and 37 participants with PPA according to the
Gorno-Tempini criteria.19 Of the 37 PPA participants, 13 had the
nonfluent variant (nfvPPA), 10 had the semantic variant (svPPA), 7
had the logopenic variant (lvPPA), and 7 did not fit criteria for any of
the 3 variants (PPA-NOS, not otherwise specified). We did not
include patients fulfilling criteria for lvPPA in the overall FTD
analysis because they are likely to have underlying Alzheimer disease
pathologically.1,2 Data were compared with data from 28 healthy
control participants matched for age and sex who had been collected
as part of a study of neurodegenerative disease (table 1). Twenty-four of
the FTD participants carried a pathogenic mutation: 9 with an
expansion in C9orf72 (8 with bvFTD, 1 with nfvPPA), 11 with an
MAPT mutation (all with bvFTD), and 4 with a GRN mutation
(1 with bvFTD, 1 with nfvPPA, and 2 with PPA-NOS). No
mutations were found in the other participants. No significant
differences were noted in age or sex between any of the groups, and
no significant difference in disease duration was seen between the
clinical or genetic FTD subgroups.
Standard protocol approvals, registrations, and patient
consents. Approval for the study was obtained from the local
ethics committee, and all participants provided written consent
to take part.
Measurement of NfL concentrations. Serum samples were
collected from each of the participants and then processed,
divided into aliquots, and frozen at 2808C according to standard-
ized procedures. Serum NfL concentrations were measured with
the NF-Light assay from UmanDiagnostics (Umeå, Sweden) and
transferred onto the Simoa platform with a home-brew kit
(Quanterix Corp, Boston, MA). Detailed instructions can be
found in the Simoa Homebrew Assay Development Guide
(Quanterix). In short, paramagnetic carboxylated beads (catalog
no. 100451, Quanterix) were activated by adding 5% (vol/vol)
10 mg/mL 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide
(catalog no. 100022, Quanterix) to a magnetic beads solution
with 1.43106 beads/mL. After a 30-minute incubation at room
temperature, the beads were washed with a magnetic separator,
and an initial volume, i.e., 1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide 1 bead solution volume in the previous step, of
0.3 mg/mL ice cold solution of the capture antibody (UD1,
UmanDiagnostics) was added. After a 2-hour incubation on
a mixer (2,000 rpm, Multi-Tube Vortexer, Allsheng, China) at
room temperature, the beads were washed, and an initial reaction
volume of blocking solution was added. After 3 washes, the
conjugated beads were suspended and stored at 48C pending
analysis. Before analysis, the beads were diluted to 2,500
beads/mL in bead diluent. The detection antibody (1 mg/mL,
UD2, UmanDiagnostics) was biotinylated by adding 3%
(vol/vol) 3.4 mmol/L EZ‐Link NHS‐PEG4‐Biotin (Quanterix),
followed by a 30-minute incubation at room temperature. Free
biotin was removed with spin filtration (Amicon Ultra-2, 50
kDa, Sigma, St. Louis, MO), and the biotinylated antibody was
stored at 48C pending analysis. The serum samples were assayed in
duplicate on a Simoa HD-1 instrument (Quanterix) using a 2-step
assay dilution protocol that starts with an aspiration of the bead
diluent from 100 mL conjugated beads (2,500 beads/mL), followed
by the addition of 20 mL biotinylated antibody (0.1 mg/mL) and
100 mL of 4-fold diluted sample (or undiluted calibrator) to the
Table 1 Demographic characteristics of the study participants
Disease group Controls Total FTD bvFTD FTD-MND nfvPPA svPPA lvPPA PPA-NOS
No. 28 67 34 3 13 10 7 7
Age, mean (SD), y 63.9 (7.2) 64.5 (7.9) 63.0 (8.3) 65.0 (0.3) 67.5 (9.7) 65.2 (6.4) 65.6 (5.9) 63.9 (5.2)
Male sex, % 46.4 61.2 73.5 66.7 23.1 60.0 71.4 71.4
Disease duration, mean (SD), y NA 5.5 (3.7) 6.2 (4.6) 6.0 (4.6) 3.8 (1.5) 6.0 (2.1) 6.4 (2.9) 4.5 (2.5)
Serum NfL, mean (SD), pg/mL 19.6 (8.2) 77.9 (51.3) 57.8 (33.1) 195.0 (69.9) 82.5 (33.8) 95.9 (33.0) 49.5 (19.4) 91.2 (86.6)
Abbreviations: bvFTD 5 behavioral variant of frontotemporal dementia; FTD 5 frontotemporal dementia; FTD-MND 5 frontotemporal dementia with motor
neuron disease; lvPPA5 logopenic variant of primary progressive aphasia; NA5 not applicable; NfL5 neurofilament light chain; nfvPPA5 nonfluent variant of
primary progressive aphasia; PPA-NOS 5 primary progressive aphasia not otherwise specified; svPPA 5 semantic variant of primary progressive aphasia.
Total FTD does not include lvPPA.
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bead pellet. For both samples and calibrator, the same diluent was
used (phosphate-buffered saline; 0.1% Tween-20; 2% bovine
serum albumin; 10 mg/mL TRU Block [Meridian Life Science,
Inc, Memphis, TN]). After a 47-cadence incubation (1 cadence
5 45 seconds), the beads were washed, followed by the addition of
100 mL streptavidin-conjugated b-galactosidase (150 pmol/L,
catalog No. 100439, Quanterix). This was followed by a 7-
cadence incubation and a wash. Before reading, 25 mL resorufin
b2D-galactopyranoside (catalog No. 100017, Quanterix) was
added. The calibrator curve was constructed by use of the standard
from the NfL ELISA (NF-Light, UmanDiagnostics) in triplicate. The
lower limits of detection and quantification, as defined by the
concentration derived from the signal of blank samples (sample
diluent) 1 3 and 10 SD, were 0.97 and 2.93 pg/mL, respectively.
To evaluate the linearity of the assay, 6 different samples were analyzed
at 4- (default), 8-, and 16-fold dilution, and the average coefficient of
variation for the concentration measured at the different dilutions
was 11.5%. All samples were measured as duplicates. The mean
coefficient of variation of duplicate concentrations was 4.3%. In
addition, a quality control sample was measured in duplicate on each
of the 7 runs used to complete the study. The intra-assay coefficient
of variation for this sample was ,10%. All measurements were
performed by board-certified laboratory technicians in one round
of experiments using one batch of reagents.
Psychometric assessment. Forty-seven participants had psy-
chometric testing at baseline, usually on the same day as serum
sampling but at a maximum of 6 months from the time of sample
collection (mean interval 0.0 years [SD 0.2 years]): 22 with
bvFTD, 2 with FTD-MND, and 23 with PPA (9 with
nfvPPA, 9 with svPPA, and 5 with PPA-NOS). Twenty-nine
participants had follow-up psychometric testing at an interval
of 1.1 years (SD 0.2 years): 11 with bvFTD, 2 with FTD-
MND, and 16 with PPA (5 with nfvPPA, 7 with svPPA, and 4
with PPA-NOS). Testing included the Wechsler Abbreviated
Scale of Intelligence Vocabulary, Block Design, Similarities,
and Matrices subtests20; the Recognition Memory Tests for
Faces and Words21; the Graded Naming Test22; the Graded
Difficulty Calculation Test23; and the Delis-Kaplan Executive
Function System Color-Word Interference Test,24 as well as the
Mini-Mental State Examination.25
Neuroimaging analysis. Forty-six of the participants with
FTD had volumetric T1 brain MRI on a 3T Siemens Trio scan-
ner performed usually on the same day as serum sampling but at
a maximum of 6 months from the time of sample collection (mean
interval 0.0 years [SD 0.2 years]): 24 with bvFTD, 2 with FTD-
MND, and 20 with PPA (8 with nfvPPA, 8 with svPPA, 4 with
PPA-NOS). Twenty-nine participants had a follow-up scan at 1.1
years (SD 0.4 years) after the baseline scan: 13 with bvFTD, 2
with FTD-MND, and 14 with PPA (5 with nfvPPA, 6 with
svPPA, and 3 with PPA-NOS). Whole-brain volumes were
measured with a semiautomated segmentation method26 with
annualized whole-brain atrophy rates calculated with the
boundary shift integral.27 Individual lobar cortical volumes were
measured with a multiatlas segmentation propagation approach
following the brainCOLOR protocol (www.braincolor.org),
combining regions of interest to calculate gray matter volumes for
each lobe.28,29 Annualized lobar atrophy rates were calculated using
the differences in volumes between the baseline and follow-up scans
and dividing by the interval between scans.
Statistical analysis. Serum NfL concentrations were initially
compared between the control group and the total FTD group.
The Levene test for homogeneity demonstrated unequal variances
between these 2 groups (Levene statistic 5 22.8; p , 0.001);
therefore, the Welch t test (without assumptions for equal variance)
was used to compare the groups. Serum NfL data were normally
distributed (Kolmogorov-Smirnov test), so an analysis of variance
was used to compare mean serumNfL concentrations across each of
the clinical subgroups (bvFTD, FTD-MND, nfvPPA, svPPA,
lvPPA, and PPA-NOS) and across the genetic FTD subgroups
(MAPT, GRN, and C9orf72), and to compare each of these
subgroups with the control group. To allow for unequal variance,
the Games-Howell correction was used for post hoc pairwise
comparisons between groups. The same statistical methods were
also used to compare NfL levels between the genetic subgroups
and between each of these groups and the control group. The
Pearson correlation coefficient was used to examine the association
Figure 1 Serum neurofilament light chain concentrations in participants by (A)
clinical diagnosis and (B) genetic status
All genetic FTD patients have behavioral variant of frontotemporal dementia (bvFTD) except
for those *with nonfluent variant of primary progressive aphasia (nfvPPA) and **with primary
progressive aphasia not otherwise specified (PPA-NOS). FTD-MND 5 frontotemporal
dementia–motor neuron disease; lvPPA 5 logopenic variant of primary progressive aphasia;
svPPA 5 semantic variant of primary progressive aphasia.
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between serum NfL concentrations and each of the cognitive and
imaging measures (with a Bonferroni correction for multiple
comparisons also assessed, i.e., p , 0.005 for the cognitive
measures and p , 0.007 for the imaging measures).
RESULTS Serum NfL concentrations in the control
and total FTD groups and in each clinical subgroup
are shown in table 1. The lowest serum NfL concen-
tration in the study (7.2 pg/mL) was well above the
lower limits of detection and quantification of the
assay. Serum NfL concentrations were significantly
higher in the total FTD group vs controls (mean
77.9 pg/mL [SD 51.3 pg/mL] and 19.6 pg/mL [SD
8.2 pg/mL] respectively; mean difference5 58.3 pg/mL,
95% confidence interval 45.4–71.1; p, 0.001). In dis-
tinguishing FTD from controls, a cutoff of 33 pg/mL
gave a sensitivity of 84% and specificity of 96%. Serum
NfL concentrations were also significantly higher in the
majority of the clinical FTD subgroups compared with
the control group (Welch statistic 5 25.1, df 5, 13.2;
p, 0.001) (figure 1A, table 2). Compared with controls,
serum NfL concentrations were higher in patients
with bvFTD, nfvPPA, and svPPA. Although pa-
tients with FTD-MND had higher mean serum
NfL concentrations than controls (and all of the
other groups), this difference did not reach statistical
significance, likely because of the small sample size of
the FTD-MND group. Serum NfL concentrations did
not differ significantly between any of the clinical FTD
subgroups, although there was a (not significant) trend
toward a higher level in patients with svPPA compared
with patients with bvFTD (mean difference 5 38.1,
p 5 0.070). There was a significantly higher level in
patients with svPPA compared with lvPPA (mean
difference 5 46.3, p 5 0.032).
Mean NfL concentrations were higher than con-
trols in each of the genetic subgroups (figure 1B, table
3): 138.5 pg/mL (SD 103.3 pg/mL) in GRN, 79.2
pg/mL (SD 48.2 pg/mL) in C9orf72, and 40.5 pg/
mL (SD 20.9 pg/mL) inMAPTmutations. However,
only theMAPT subgroup (mean difference from con-
trols5 20.8, 95% confidence interval5 1.4–40.3, p
5 0.035) and the C9orf72 subgroup (mean difference
from controls 5 59.5, 95% confidence interval 5
8.0–111.0, p 5 0.025) were significantly different,
with the lack of difference in the GRN subgroup
likely due to small sample size (table 3). Despite the
apparent larger mean NfL levels in GRN and C9orf72
compared with MAPT mutations, there was no sig-
nificant difference in levels between the genetic sub-
groups (table 3).
Baseline and longitudinal cognitive and imaging
measures are shown in table 4. SerumNfL concentrations
Table 2 Comparison of serum neurofilament light chain concentrations between the disease subgroups and control group
bvFTD FTD-MND nfvPPA svPPA lvPPA PPA-NOS
Controls 238.2 (5.9) 2175.3 (40.4) 262.9 (9.5) 276.2 (10.5) 229.9 (7.5) 271.6 (32.8)
p ,0.001 0.185 ,0.001 0.001 0.053 0.413
bvFTD 2137.2 (40.8) 224.7 (10.9) 238.1 (11.9) 8.3 (9.3) 271.6 (32.8)
p 0.276 0.308 0.070 0.968 0.413
FTD-MND 112.4 (41.5) 99.1 (41.7) 145.4 (41.0) 103.8 (51.9)
p 0.374 0.451 0.248 0.509
nfvPPA 213.3 (14.0) 33.0 (11.9) 28.7 (34.0)
p 0.959 0.136 1.000
svPPA 46.3 (12.7) 4.7 (34.4)
p 0.032 1.000
lvPPA 241.7 (33.5)
p 0.857
Abbreviations: bvFTD 5 behavioral variant of frontotemporal dementia; FTD-MND 5 frontotemporal dementia with motor neuron disease; lvPPA 5
logopenic variant of primary progressive aphasia; nfvPPA 5 nonfluent variant of primary progressive aphasia; PPA-NOS 5 primary progressive aphasia
not otherwise specified; svPPA 5 semantic variant of primary progressive aphasia.
Values are given as mean difference in serum neurofilament concentration between groups (SEM) and refer to comparison of rows vs columns.
Table 3 Comparison of serum neurofilament
light chain concentrations between the
genetic subgroups and control group
MAPT GRN C9orf72
Control 220.8 (6.5) 2118.8 (51.7) 259.5 (16.2)
p 0.035 0.277 0.025
MAPT 298.0 (52.0) 238.7 (17.3)
p 0.386 0.175
GRN 59.3 (54.1)
p 0.712
Values are given as mean difference in serum neurofila-
ment concentration between groups (SEM) and refer to
comparison of rows vs columns.
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correlated with baseline measures of executive dysfunc-
tion (Wechsler Abbreviated Scale of Intelligence similar-
ities [r520.32, p5 0.03] and Delis-Kaplan Executive
Function System Color-Word Interference ink color
naming task [r520.35, p5 0.03]) but not with other
baseline psychometric tests or with longitudinal changes
in psychometric measures. However, no cognitive meas-
ures survived correction for multiple comparisons. There
were also no significant correlations with baseline brain
volumes.However, serumNfL levels were correlated with
rates of whole brain (r 5 0.46, p 5 0.01), frontal lobe
(r 5 0.53, p 5 0.003; figure 2), and parietal lobe (r 5
0.38, p 5 0.04) atrophy, although not with other lobar
atrophy rates. Only the correlation with frontal lobe atro-
phy rate survived correction for multiple comparisons.
DISCUSSION Using an ultrasensitive immunoassay,
we show that serum NfL concentrations are raised in
FTD and that higher concentrations are associated
with faster rates of brain atrophy. These findings suggest
that serum NfL concentrations reflect the intensity of
the disease in FTD and that higher concentrations are
associated with a more rapid disease progression.Within
the FTD subtypes, there was a tendency for groups with
probable TDP-43 pathology (svPPA and FTD-MND
clinically, GRN and C9orf72 mutations genetically) to
have raised levels compared with those associated with
tau pathology (MAPT mutations), although within all
groups there is substantial variability. With a lower limit
of quantification of 0.26 pg/mL, all samples, including
those from normal controls, could be reliably quantified,
which is an advantage over earlier studies on serum NfL
in other conditions.14,30–32
The results of this study are consistent with those
found in previous CSF studies of NfL concentrations
in FTD: levels are consistently higher in patients with
FTD4–11 and tend to be increased in those with probable
TDP-43 pathology.10,11 Certainly for genetic FTD, for
which GRN and C9orf72 mutations are associated with
TDP-43 pathology, this is consistent with the more rapid
progression (and shorter disease duration) seen in many
patients within these 2 mutation groups (independent of
clinical syndrome) compared with the relatively slower
progression of patients with MAPT mutations (which is
associated with tau pathology).33 One previous study also
suggested a correlation of CSF NfL with measures of
disease severity and, consistent with our study, showed
an association of levels with frontal lobe atrophy.11
We found that serum NfL levels were correlated
with the rate of subsequent brain atrophy but not
with the baseline brain volumes. Measures of brain
atrophy are likely to be better measures of the disease
intensity than just a single cross-sectional measure of
the whole-brain or lobar volumes, which reflect dis-
ease duration and normal variation as well as disease
activity. Serum NfL levels correlated with baseline
measures of executive function but not with longitu-
dinal measures. A number of the patients had scored
at near the floor on executive tasks at baseline; there-
fore, there is less ability to measure progression with
such measures when assessed longitudinally.
It will be important to investigate patients at differ-
ent stages of the disease because this may influence the
association between NfL and rates of atrophy. The
Genetic Frontotemporal Dementia Initiative (GENFI)
study (www.genfi.org.uk) has recently shown that path-
ologic rates of brain atrophy appear to start up to 10
years before symptom onset but are variable between
different genetic mutations.29 If serum NfL concentra-
tions represent measures of disease intensity, then we
would predict that levels would start to increase around
10 years before onset and may provide a useful non-
invasive marker of proximity to symptom onset.
There are a number of limitations to this study. In
particular, the majority of the patients did not have
Table 4 Cognitive and imaging characteristics of the frontotemporal dementia
study participants
Baseline, mean (SD) Longitudinal, mean (SD)
Cognitive measures
Participants, n 47 29
MMSE 23.8 (5.7) 21.7 (5.0)
WASI vocabulary 4.4 (4.4) 20.9 (2.9)
WASI block design 8.7 (4.3) 20.4 (2.6)
WASI similarities 5.9 (4.3) 21.5 (3.1)
WASI matrices 9.4 (4.3) 0.1 (2.6)
RMT faces 5.2 (4.1) 20.9 (3.7)
RMT words 6.1 (4.5) 21.5 (4.1)
Graded naming test 4.2 (4.4) 21.7 (3.0)
Graded difficulty calculation test 7.8 (5.0) 20.9 (2.4)
D-KEFS Color-Word Interference Test 6.1 (5.1) 21.7 (2.5)
Imaging measures
Participants, n 46 29
Whole brain 72.6 (5.0) 1.9 (1.5)
Frontal 10.4 (1.0) 2.2 (2.7)
Temporal 7.0 (0.9) 2.7 (2.4)
Parietal 6.0 (0.5) 1.2 (2.9)
Occipital 4.9 (0.4) 0.7 (2.5)
Insula 0.8 (0.1) 2.6 (2.6)
Cingulate 1.6 (0.1) 1.2 (2.0)
Abbreviations: D-KEFS 5 Delis-Kaplan Executive Function System; MMSE 5 Mini-Mental
State Examination; RMT 5 Recognition Memory Test; WASI 5 Wechsler Abbreviated Scale
of Intelligence.
Baseline cognitive measures are standard scores except for the MMSE (out of 30).
Longitudinal cognitive scores are annualized change in standard score (or change in MMSE
score); a negative score is a decrease in score. Baseline brain volumes are expressed as
a percentage of total intracranial volume (measured in Statistical Parameter Mapping
[SPM12]). Longitudinal imaging measures are annualized rates of atrophy (%).
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pathologic confirmation of the cause of their illness, and
future studies should investigate serum NfL levels in dif-
ferent FTD pathologies. Although there is a relatively
large number of cases for a study of a rare disorder like
FTD, the individual numbers are small in each subgroup
(particularly the FTD-MND group), and it would be
useful for future studies to investigate larger groups of
the individual clinical and genetic subtypes. Clinical
measures of disease staging in FTD have only recently
been designed (such as the Frontotemporal Lobar
Degeneration-Clinical Dementia Rating34 and Fronto-
temporal Dementia Rating Scale35) and were not avail-
able in this cohort; it will be important for future studies
to compare such measures with serum NfL levels.
Higher serum NfL concentrations are associated
with more rapid brain atrophy and may therefore
reflect disease intensity in FTD. Because blood sam-
pling is less invasive and has better patient acceptabil-
ity than lumbar puncture, serum NfL may provide
important prognostic information and prove to be
a useful outcome measure for clinical trials in FTD.
However, further studies will be required to under-
stand the factors affecting the variability in NfL con-
centration and to determine whether it can be a useful
measure within individual patients.
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Comment:
“If you can’t measure it, you can’t improve it” (Lord Kelvin)
In clinical practice, disability and its progression are notoriously difficult to
quantify, urging the need for reliable soluble biomarkers for neuroaxonal damage.
Neurofilament light chain (NfL) is a scaffolding protein of the neural cytoskeleton
with important roles in axonal and dendritic branching and growth. After neuronal
damage, NfL levels in the CSF increase and thus are considered a highly specific,
real-time biomarker of axonal injury.
In the case of serum NfL, the single-molecule array technology substantially im-
proves analytical sensitivity to an extent that measurements in blood-derived samples
may be used as surrogate endpoints in neuroprotection trials or even in daily practice
in the relatively near future.1,2 The ultrasensitive assay used by Rohrer and colleagues1
allowed reliable NfL measurements in all serum samples, including healthy controls,
a giant stride for a biomarker that is independent of CSF and hence applicable in
a routine clinical setting. Moreover, the authors found that their assay is quantitative:
higher concentrations were associated with more rapid course of frontal lobe atrophy
(r 5 0.53, p 5 0.003).1 A strong correlation between CSF and blood NfL levels has
been convincingly shown across a number of neurologic diseases, so the lack of CSF
data in the current study does not limit the relevance of the findings.
Rohrer and colleagues1 provide strong evidence supporting the potential role
of serum NfL as a disease progression marker in frontotemporal dementia. Their
results are well in line with recent findings in experimental mouse models of pro-
teopathic (tau, b-amyloid, and a-synuclein) neurodegenerative diseases in which
NfL levels in CSF and plasma were responsive to experimental manipulation or
targeted therapy.3 Future studies in large, well-characterized patient cohorts are
warranted to further characterize NfL as a primary biomarker to predict and mon-
itor disease progression and to assess treatment responses.
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marker of disease progression in mouse models and in neurodegenerative diseases.
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